Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme

Journal of Neurosurgery

Volumn 108, Issue 2, 2008, Pages 236-242

  Darakchiev, Borimir J ^a   Albright, Robert E ^a   Breneman, John C ^a   Warnick, Ronald E ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

BCNU wafer; Brachytherapy; Glioblastoma multiforme; Interstitial chemotherapy

Indexed keywords

CARMUSTINE; IODINE 125;

ADULT; ARTICLE; BRACHYTHERAPY; BRAIN NECROSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EVALUATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; HYPERBARIC OXYGEN; IMPLANT; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SURVIVAL TIME; TUMOR RECURRENCE;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRACHYTHERAPY; BRAIN; BRAIN NEOPLASMS; CARMUSTINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; HYPERBARIC OXYGENATION; IODINE RADIOISOTOPES; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NECROSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; RADIOPHARMACEUTICALS; SAFETY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38949131870     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/JNS/2008/108/2/0236     Document Type: Article

References (30)

1. Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, et al: Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 36:433-441, 1996
2. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012, 1995
3. Chan JL, Lee SW, Fraass BA, Normolle DP, Greenberg HS, Junck LR, et al: Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635-1642, 2002
4. Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, et al: Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557-564, 2005
5. Chow KL, Gobin YP, Cloughesy T, Sayre JW, Villablanca JP, Vinuela F: Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol 21:471-478, 2000
6. Dirks P, Bernstein M, Muller PJ, Tucker WS: The value of reoperation for recurrent glioblastoma. Can J Surg 36:271-275, 1993
7. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585-2597, 1993
8. Florell RC, Macdonald DR, Irish WD, Bernstein M, Leibel SA, Gutin PH, et al: Selection bias, survival, and brachytherapy for glioma. J Neurosurg 76:179-183, 1992
9. Giese A, Kucinski T, Knopp U, Goldbrunner R, Hamel W, Mehdorn HM, et al: Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351-360, 2004
10. Gutin PH, Bernstein M, Sano Y, Deen DF: Combination therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea and low dose rate radiation in the 9L rat brain tumor and spheroid models: implications for brain tumor brachytherapy. Neurosurgery 15:781-786, 1984
11. Halligan JB, Stelzer KJ, Rostomily RC, Spence AM, Griffin TW, Berger MS: Operation and permanent low activity 125I brachytherapy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 35:541-547, 1996
12. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911, 1980
13. Huncharek M, Muscat J: Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res 18:1303-1311, 1998
14. Larson DA, Suplica JM, Chang SM, Lamborn KR, McDermott MW, Sneed PK, et al: Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro-oncol 6:119-126, 2004
15. Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M, Wronski M: Fractionated stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma multiforme: a preliminary report. Int J Radiat Oncol Biol Phys 40:661-666, 1998
16. Lelieveld P, Brown JM, Goffinet DR, Schoeppel SL, Scoles M: The effect of BCNU on mouse skin and spinal cord in single drug and radiation exposures. Int J Radiat Oncol Biol Phys 5:1565-1568, 1979
17. Moringlane JR, Voges M, Huber G, Muller J, Leetz HK: Short-term CT and MR changes in brain tumors following 125I interstitial irradiation. J Comput Assist Tomogr 21:15-21, 1997
18. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS: Combined modality approach to treatment of malignant gliomas-re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr 6:279-284, 1988
19. Patel S, Breneman JC, Warnick RE, Albright RE Jr, Tobler WD, van Loveren HR, et al: Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 46:1123-1128, 2000
20. Paterson AH, English D: The effect of BCNU combined with total body irradiation or cyclophosphamide on survival of dogs after autologous marrow grafts. Int J Radiat Oncol Biol Phys 5:1585-1587, 1979
21. Postma TJ, van Groeningen CJ, Witjes RJ, Weerts JG, Kralendonk JH, Heimans JJ: Neurotoxicity of combination chemotherapy with procarbazine, CCNU and vincristine (PCV) for recurrent glioma. J Neurooncol 38:69-75, 1998
22. Schenken LL, Burholt DR, Hagemann RF, Lesher S: The modification of gastrointestinal tolerance and responses to abdominal irradiation by chemotherapeutic agents. Radiology 120:417-420, 1976
23. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298, 2000
24. Simpson JR, Horton J, Scott C, Curran WJ, Rubin P, Fischbach J, et al: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 26:239-244, 1993
25. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
26. Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, et al: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 41:44-49, 1997
27. Veninga T, Langendijk HA, Slotman BJ, Rutten EH, van der Kogel AJ, Prick MJ, et al: Reirradiation of primary brain tumours: survival, clinical response and prognostic factors. Radiother Oncol 59:127-137, 2001
28. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES: In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92-97, 1997
29. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al: A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5:79-88, 2003
30. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999